First Author | Bleux C | Year | 1995 |
Journal | J Interferon Cytokine Res | Volume | 15 |
Issue | 4 | Pages | 351-7 |
PubMed ID | 7627810 | Mgi Jnum | J:29308 |
Mgi Id | MGI:76837 | Doi | 10.1089/jir.1995.15.351 |
Citation | Bleux C, et al. (1995) A mouse placental immunoregulatory factor different from transforming growth factor beta. J Interferon Cytokine Res 15(4):351-7 |
abstractText | Of the growth-promoting factors, transforming growth factor beta (TGF-beta) has been most clearly shown to act as a potent regulator of inflammation and immunity. It is highly suppressive for T and B lymphocyte proliferation, cytotoxic T lymphocyte generation, and lymphokine-activated killer cell development, as well as natural killer cell activity. Moreover, there is accumulating evidence that TGF-beta also may contribute to impaired immune surveillance of tumor development. In previous work, we isolated and described a 40 kD glycoprotein extracted from mouse placenta. This placental factor (PF) is also a potent immune modulator in vivo: it is highly inhibitory of secondary antibody responses as well as cellular responses, such as local graft-versus-host reactions. Because placenta has been shown to be a major source of TGF-beta and several reports have indicated an important role for TGF-beta in the immunosuppressive mechanisms taking place during the course of mammalian gestation, we have looked for the presence of TGF-beta in our placental factor preparations. Our results clearly indicate that they do not contain TGF-beta or TGF-beta-like molecules by the following criteria: (1) no inhibition of Mv-1 Lu cell proliferation at any dose tested; (2) no band detected by immunoblotting using different polyclonal reagents specific for TGF-beta 1; and (3) no activity retained on or eluted from an affinity column made of immobilized monoclonal antibody against TGF-beta 2. Aliquots of the same preparations retained their full immune inhibitory capacity in vivo throughout the various assays.(ABSTRACT TRUNCATED AT 250 WORDS) |